Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 25, Issue 4, Pages 403-413Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.07.013
Keywords
Multiple sclerosis; EAE; Therapy; Cytokines; Th17
Categories
Funding
- German Research Council (DFG) [SFB-TRR128]
Ask authors/readers for more resources
Multiple sclerosis (MS), an autoimmune neurological disorder, is driven by self-reactive T helper (Th) cells. Research on the role of Th17 lymphocytes in MS pathogenesis has made significant progress in identifying various immunological as well as environmental factors that induce the differentiation and expansion of these cells, different subsets of Th17 cells with varying degrees of pathogenicity, and the role of the secreted effector cytokines. While approved therapies for MS offer significant benefit to patients, there remain unmet needs. Ongoing clinical trials aim to translate the advanced knowledge of Th17 cytokines to improved therapies. This review discusses the current status and future developments of research into the role of Th17 and related cytokines in MS pathogenesis and therapy. (C) 2014 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available